SCHEMBL832295

SCHEMBL832295

CCOC(=O)c1c(CC(C)C)cc(-c2cccc(F)c2)nc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TRPM8 Q7Z2W7 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 2/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
ADORA3 P0DMS8 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831580 0.89 ALDH1A1 (0.51) ALDH1A1L3MBTL1SMN1; SMN2KDM4EMAPT
SCHEMBL830856 0.87 ALDH1A1 (0.50) ALDH1A1L3MBTL1SMN1; SMN2KDM4EMAPT
SCHEMBL831148 0.86 KMO (0.44) TRPM8SMN1; SMN2KDM4ECNR2
SCHEMBL3342312 0.82 ALDH1A1 (0.54) ALDH1A1L3MBTL1TRPM8SMN1; SMN2KDM4E
SCHEMBL831717 0.80 CNR2 (0.41) TRPM8JAK2JAK3ADORA3CNR2
SCHEMBL830007 0.78 ALDH1A1 (0.43) ALDH1A1L3MBTL1SMN1; SMN2KDM4EMAPT
SCHEMBL833067 0.78 CNR2 (0.43) TRPM8SMN1; SMN2KDM4EADORA3CNR2
SCHEMBL831887 0.76 ALDH1A1 (0.47) ALDH1A1L3MBTL1TRPM8SMN1; SMN2KDM4E
SCHEMBL4426818 0.76 RAB9A (0.60) ALDH1A1L3MBTL1TRPM8SMN1; SMN2KDM4E
SCHEMBL3340782 0.75 ALDH1A1 (0.49) ALDH1A1L3MBTL1TRPM8SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT ALDH1A1 1238/4885L3MBTL1 823/4885TRPM8 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.